Skip to Main Content

Journal Articles (DOI Links)

Adaptation of an rVSV Ebola Vaccine Purification Process for Rapid Development of a Viral Vaccine Candidate for SARS-CoV-2

External Link · Published 2026-11-14 · 1 min read

Journal Article

Kuczynski, L. E., Shallow, J. R., Watson, M. P., Homsy, M. L., Svab, T., Gruber, A., Rustandi, R. R., Hu, J., & Winters, M. A. (2024). Adaptation of an rVSV Ebola vaccine purification process for rapid development of a viral vaccine candidate for SARS-CoV-2. Biotechnology Journal, 19(1), e2300041.

Researchers at Merck & Co., working with the International AIDS Vaccine Initiative, adapted the downstream purification process behind ERVEBO® (rVSVΔG-ZEBOV-GP) to produce an investigational rVSVΔG-SARS-CoV-2 vaccine candidate. The paper walks through clarification, trypsin treatment, chromatography, ultrafiltration and sterile filtration for the new candidate, and reports where the process had to change.

One of those changes concerns formulation order. The team moved the recombinant human serum albumin (rHSA) formulation step ahead of sterile filtration, and used rHSA from InVitria.

Why This Matters

Enveloped viral vectors lose infectivity at membrane surfaces. Filtering equal-volume splits of the same ultrafiltration product showed how much is recoverable when albumin is present in the feed and the pre-use flush.

  • Viral potency step yield rose from 42% with buffer alone to 74% when the product was formulated with rHSA before 0.22 µm filtration.
  • S protein step yield rose from 27% to 59%, and N protein from 41% to 72%, across the same filtration.
  • The authors attribute the gain to rHSA saturating the membrane with additional protein, reducing interactions between the virus and the membrane surface.
  • On the basis of this result, the formulation step was moved ahead of sterile filtration in the process.

About This Resource

This is a peer-reviewed publication by authors at Merck & Co., Inc. It is summarized here because the recombinant human serum albumin used in the work was supplied by InVitria. The full article is available from the publisher. InVitria supplies recombinant human serum albumin for vaccine and viral vector formulation as Exbumin® and Optibumin® 25.

More resources

Keep reading.

Talk to a Scientist

See how rHSA performs in your media.

Send us your cell line and formulation and we will help you design a side-by-side evaluation against your current albumin.